Brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce sales of $3.00 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $4.00 million. Crispr Therapeutics posted sales of $1.09 million in the same quarter last year, which would indicate a positive year over year growth rate of 175.2%. The company is scheduled to issue its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $7.83 million for the current fiscal year, with estimates ranging from $4.00 million to $15.00 million. For the next financial year, analysts forecast that the business will report sales of $19.33 million, with estimates ranging from $8.00 million to $40.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.03). Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.50 million. During the same period in the prior year, the firm posted ($0.62) EPS. The business’s revenue was down 78.6% compared to the same quarter last year.
A number of analysts have commented on CRSP shares. BTIG Research started coverage on Crispr Therapeutics in a research report on Thursday, February 7th. They set a “buy” rating and a $43.00 price target for the company. Zacks Investment Research cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. William Blair started coverage on Crispr Therapeutics in a research report on Wednesday, March 13th. They set a “market perform” rating for the company. BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Finally, Evercore ISI started coverage on Crispr Therapeutics in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $47.64.
In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of Crispr Therapeutics stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares in the company, valued at approximately $7,840,360.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 37.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Valeo Financial Advisors LLC raised its stake in shares of Crispr Therapeutics by 71.4% during the 1st quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after buying an additional 302 shares during the last quarter. Kore Private Wealth LLC purchased a new position in shares of Crispr Therapeutics in the 1st quarter valued at about $27,000. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics in the 1st quarter valued at about $38,000. Resources Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics in the 4th quarter valued at about $43,000. Finally, Benjamin F. Edwards & Company Inc. increased its stake in shares of Crispr Therapeutics by 96.7% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,627 shares of the company’s stock valued at $46,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.
Shares of CRSP opened at $35.99 on Tuesday. Crispr Therapeutics has a one year low of $22.22 and a one year high of $70.09. The company has a quick ratio of 15.84, a current ratio of 15.84 and a debt-to-equity ratio of 0.08. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -10.46 and a beta of 2.94.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.